{"id":5723,"date":"2024-05-07T11:16:00","date_gmt":"2024-05-07T16:16:00","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5723"},"modified":"2025-06-27T11:43:50","modified_gmt":"2025-06-27T16:43:50","slug":"nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaciones en la pr\u00f3xima reuni\u00f3n anual de ASGCT y el Congreso Mundial de Retina"},"content":{"rendered":"
\n
\n
\n

<\/h2>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a07 de mayo de 2024<\/span><\/span>\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias g\u00e9nicas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que sus plataformas de terapia g\u00e9nica con opsina multicaracter\u00edstica (MCO) viral y administrada por l\u00e1ser se presentar\u00e1n en m\u00faltiples presentaciones en la feria.\u00a0Reuni\u00f3n Anual de la ASGCT 2024<\/a>\u00a0y el\u00a0Congreso Mundial de Retina<\/a>, retenido en\u00a0Baltimore, Maryland<\/span>\u00a0y\u00a0Fort Lauderdale, Florida<\/span>, respectivamente, en mayo.<\/p>\n

Los detalles son los siguientes:<\/p>\n

Reuni\u00f3n anual de la Sociedad Estadounidense de Terapia Gen\u00e9tica + Celular (ASGCT) 2024<\/a><\/b><\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0An\u00e1lisis longitudinal de BCVA y reconocimiento de objetos de campo cercano en la terapia optogen\u00e9tica independiente de la mutaci\u00f3n MCO-010 en dosis baja o alta para la retinitis pigmentosa: resultados de 12 meses de una fase\u00a02b<\/span>\/3 Ensayo cl\u00ednico aleatorizado, controlado de forma simulada, enmascarado por el paciente y el evaluador (RESTORE)<\/a>
\nN\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0917
\nTipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
\nT\u00edtulo de la sesi\u00f3n:<\/b>\u00a0P\u00f3steres del mi\u00e9rcoles: Ensayos de terapia g\u00e9nica \u2013 Modificaci\u00f3n in vivo
\nFecha de la sesi\u00f3n:<\/b>\u00a08 de mayo de 2024
\nTiempo de sesi\u00f3n:\u00a0<\/b>12:00 \u2013\u00a07:00 p.m. hora del este<\/span>
\nPresentador:<\/b>\u00a0Samuel Barone, MD, director m\u00e9dico<\/p>\n

T\u00edtulo de presentaci\u00f3n:<\/b>\u00a0Administraci\u00f3n con l\u00e1ser no viral dirigido de genes de opsina multicaracter\u00edsticos para el tratamiento de la atrofia geogr\u00e1fica<\/a>
\nN\u00famero de presentaci\u00f3n:<\/b>\u00a0426
\nTipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de res\u00famenes orales
\nT\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Enfoques no virales para aplicaciones terap\u00e9uticas
\nFecha de la sesi\u00f3n:<\/b>\u00a011 de mayo de 2024
\nTiempo de sesi\u00f3n:\u00a0<\/b>11:15 \u2013\u00a011:30 am hora del este<\/span>
\nPresentador:<\/b>\u00a0Samarendra Mohanty, PhD, Presidente y Director Cient\u00edfico<\/p>\n

En esta charla, el Dr. Mohanty destacar\u00e1 el avance de la plataforma MCO-020 administrada por l\u00e1ser de infrarrojo cercano para el tratamiento de atrofias geogr\u00e1ficas (GA) secundarias a la degeneraci\u00f3n macular relacionada con la edad (DMAE).<\/p>\n

Congreso Mundial de Retina 2024<\/a><\/b><\/p>\n

T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapia g\u00e9nica, farmacoterapia y optogen\u00e9tica para la IRD
\nFecha de la sesi\u00f3n:<\/b>\u00a09 de mayo de 2024
\nTiempo de sesi\u00f3n:<\/b>\u00a09:05 \u2013\u00a09:35 am hora del este<\/span>
\nUbicaci\u00f3n:<\/b>\u00a0Hotel Fort Lauderdale
\nPresentador<\/b>: Samarendra Mohanty, PhD, directora cient\u00edfica<\/p>\n

El Dr. Mohanty presentar\u00e1 una actualizaci\u00f3n corporativa sobre la terapia g\u00e9nica MCO-010 de Nanoscope, independiente de mutaciones, para la restauraci\u00f3n de la visi\u00f3n en pacientes con degeneraciones retinianas hereditarias (DRH). A continuaci\u00f3n, tendr\u00e1 lugar una mesa redonda moderada por el Dr. Peter Kaiser, profesor de Oftalmolog\u00eda en el Instituto Oftalmol\u00f3gico Cole de la Facultad de Medicina Lerner de la Cl\u00ednica Cleveland.<\/p>\n

T\u00edtulo de presentaci\u00f3n:<\/b>\u00a0BCVA longitudinal y an\u00e1lisis de seguridad de la terapia optogen\u00e9tica independiente de mutaciones MCO-010 para la retinitis pigmentosa: caso de paciente de una fase\u00a02b<\/span>\u00a0Ensayo cl\u00ednico aleatorizado, controlado de forma simulada y enmascarado por el paciente y el evaluador (RESTORE)
\nT\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapia gen\u00e9tica y celular
\nFecha de la sesi\u00f3n:<\/b>\u00a010 de mayo de 2024
\nTiempo de sesi\u00f3n:<\/b>\u00a02:21 \u2013\u00a02:26 p. m. hora del este<\/span>
\nUbicaci\u00f3n:<\/b>\u00a0Hotel Fort Lauderdale
\nPresentador<\/b>: Christine Kay, MD, directora de electrofisiolog\u00eda, gen\u00e9tica de la retina y ensayos cl\u00ednicos de Vitreoretinal Associates en Gainesville,\u00a0Florida<\/span>y profesor asistente afiliado en la Universidad de\u00a0Sur de la Florida<\/span>.<\/p>\n

El Dr. Kay detallar\u00e1 las mejoras estad\u00edsticamente significativas y cl\u00ednicamente significativas en la agudeza visual observadas longitudinalmente en un individuo con retinitis pigmentosa (RP) avanzada tratado con MCO-010 en el ensayo RESTORE.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
\n<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0la fase de RESTAURACI\u00d3N\u00a02b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para RP (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la GA debida a la DMAE.<\/p>\n

Contacto de inversores:<\/b>
\nSocios Argot
\n212-600-1902
\nPR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0May 7, 2024\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its viral and laser-delivered Multi-Characteristic Opsin (MCO) gene therapy platforms will be featured in multiple presentations at the\u00a02024 ASGCT Annual Meeting\u00a0and the\u00a0Retina World Congress, being held in\u00a0Baltimore, Maryland\u00a0and\u00a0Fort Lauderdale, Florida, respectively, in May. Details […]<\/p>\n","protected":false},"author":6,"featured_media":5711,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5723","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-07T16:16:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:43:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress\",\"datePublished\":\"2024-05-07T16:16:00+00:00\",\"dateModified\":\"2025-06-27T16:43:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg\",\"datePublished\":\"2024-05-07T16:16:00+00:00\",\"dateModified\":\"2025-06-27T16:43:50+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/07\\\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia presentaciones en la pr\u00f3xima reuni\u00f3n anual de la ASGCT y en el Congreso Mundial de Retina - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-05-07T16:16:00+00:00","article_modified_time":"2025-06-27T16:43:50+00:00","og_image":[{"width":2000,"height":2000,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress","datePublished":"2024-05-07T16:16:00+00:00","dateModified":"2025-06-27T16:43:50+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/"},"wordCount":539,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/","url":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/","name":"Nanoscope Therapeutics anuncia presentaciones en la pr\u00f3xima reuni\u00f3n anual de la ASGCT y en el Congreso Mundial de Retina - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg","datePublished":"2024-05-07T16:16:00+00:00","dateModified":"2025-06-27T16:43:50+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ASGCT_RetinaWorld_LI_2024._V2.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/07\/nanoscope-therapeutics-announces-presentations-in-upcoming-asgct-annual-meeting-and-retina-world-congress-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5723"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5723\/revisions"}],"predecessor-version":[{"id":9042,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5723\/revisions\/9042"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5711"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}